• Organic revenue exceeding EUR 2.2 billion in 2025
• Organic adjusted EBITDA in excess of EUR 350 million in 2025

• Loans payable net of cash and liquid short-term investments / adjusted EBITDAaL ≤3.5x[1]
• Dividend payout ratio up to 50 per cent of net profit

"Medicover has positioned itself as a cash generative business with a persistent organic growth track record. Looking ahead, we intend to continue to capitalise on this position and our new financial targets reflect this. Our growth investments and underlying market growth supports organic revenue growth to EUR 2.2 billion, a 13.4% CAGR to 2025, alongside sustained healthy margins", says Fredrik Rågmark, CEO.

The new financial targets and the journey to beyond EUR 2.2 billion in revenue 2025 will be presented in tomorrow's Capital Markets Day.

The webcast could be watched here (https://edge.media-server.com/mmc/p/4zbyquc8).

Information on the Capital Markets Day and live stream could be found on the website (https://www.medicover.com/capital-markets-day).

For further information, please contact:

Hanna Bjellquist, Head of Investor Relations

+46 703 033 272
hanna.bjellquist@medicover.com

This information is information that Medicover AB (publ)] is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 20.00 CET on 16 February 2023.

[1] Can be exceeded over shorter periods.

Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities,laboratories and blood-drawing points and the largest markets are Poland and Germany. In 2021, Medicover had revenue of EUR 1,377 million and more than 38,000 employees. For more information, go to www.medicover.com